Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
1.3950
+0.5450 (64.12%)
NASDAQ · Last Trade: Jun 11th, 12:16 PM EDT
Detailed Quote
Previous Close
0.8500
Open
1.460
Bid
1.390
Ask
1.400
Day's Range
1.280 - 1.850
52 Week Range
0.7526 - 24.00
Volume
116,356,941
Market Cap
5.20M
PE Ratio (TTM)
-0.4415
EPS (TTM)
-3.2
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,639,905
Chart
About Helius Medical Technologies, Inc. - Class A Common Stock (HSDT)
Helius Medical Technologies is focused on developing and commercializing innovative medical devices aimed at improving treatment options for patients with neurological conditions, particularly those suffering from disorders resulting from traumatic brain injuries. The company's flagship product is designed to enhance the brain's natural ability to heal itself by leveraging neurotechnology. Helius is committed to advancing the field of neurology through rigorous scientific research and collaborations, ultimately aiming to improve outcomes and quality of life for affected individuals. Read More
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement-
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.
Shepherd Center’s Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement
